Cannabis CBD Infused Products Grow in Popularity Along With Newest Medicinal Applications and Uses

Tuesday, February 28, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

PALM BEACH, Florida, February 28, 2017 /PRNewswire/ --

The accelerating consumer acceptance and expanding legalization

of legal marijuana as well as cannabis infused products and its medicinal applications has resulted in many new opportunities for cannabis based companies and operators. Consumers can now obtain the benefits of legal marijuana without have to smoke the
substance as popularity grows for CBD infused products from skin care to medicinal therapies to infused consumer goods and water products. Cannabis, medicinal marijuana, CBD infused product companies include: Puration, Inc. (OTC: PURA), OWC Pharmaceutical Research Corp. (OTC: OWCP), Cannabis Science, Inc. (OTC: CBIS), Medical Marijuana, Inc. (OTC: MJNA) and GrowBlox Sciences, Inc. (OTC: GBLX).

Puration, Inc. (OTC: PURA) and Alkame Holdings, Inc. (ALKM) today announced that the two Companies will partner to introduce a second EVERx Bottled Water product at the upcoming Annual Arnold Sports Festival (formerly the 'Arnold Classic' named for Arnold Schwarzenegger) in Columbus, Ohio this week, starting March 2nd, 2017. PURA previously announced the launch of its EVERx CBD Infused Bottled Water to take place at the Arnold. Today, the two companies are announcing that PURA will private label ALKM's patented Alkaline Water under the EVERx brand name. Both EVERx CBD Infused Bottled Water and EVERx Alkaline Bottled Water will be launched at the Arnold. Title contender, number three ranked UFC MMA women's bantamweight fighter, Julianna Peña will be the EVERx Brand Spokesperson at the Arnold for both EVERx CBD Infused Bottled Water and EVERx Alkaline Water. Read this and more news for PURA at:

To learn more about the EVERx Brand Product Launch at the Arnold Sports Festival, follow this link EVERx BRAND LAUNCH AT THE ARNOLD SPORTS FESTIVAL

ALKM's patented technology alters the structure of water, producing a combination of characteristics that are unprecedented in the beverage industry. The ALKM technology breaks down the hydrogen bonds, reducing water's cluster size, providing a more efficient delivery system for the CBD in the EVERx CBD Infused Bottled Water, and the ALKM technology includes an optimal alkaline pH level formulated with antioxidants and electrolytes so that the EVERx Alkaline Bottled water can deliver most effective hydration available in the alkaline water market.

In other cannabis developments of note:

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, yesterday announced it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical crème compound for the treatment of psoriasis and related skin conditions. The approval follows the Company's February 1, 2017 8K filing announcing an extension to the size and scope of its efficacy study on the same compound, which began in November 2106.

Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announced late last week updates on the proposed self-medicating DPI Inhalation Device for Asthma/COPD and our Cannabinoid infused pain patch. The Company is working on the final packaging for the Cannabinoid-based Pain Patches and will roll out to partner dispensaries in the Los Angeles area very soon, joining the existing Cannabis Science product line.

Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, subsidiary, HempMeds® Brasil announced last week that the Brazilian government has authorized a doctor's prescription for the Company's hemp cannabidiol (CBD) oil product Real Scientific Hemp Oil™ (RSHO™) to treat patients in the country suffering from Multiple Sclerosis. This marks the first time that Brazil's National Health Surveillance Agency ANVISA has granted the filling of a prescription for RSHO™ to specifically help patients combat the effects of Multiple Sclerosis. Per the Multiple Sclerosis International Federation (MSIF), more than 2.5million people worldwide are affected by MS, a progressive disease of the central nervous system, for which there is currently no cure. In Brazil, MS prevalence is estimated to range from 1.36-20 per 100,000 inhabitants.

GrowBlox Sciences, Inc. (OTCQB: GBLX) announced earlier this month, filing the second in a series of patent applications for life science inventions by its wholly-owned subsidiary, Growblox Life Sciences, LLC. Inflammatory disorders represent a serious health and economic burden in the US with over $200 billion spent annually. GB Sciences' novel cannabis-based therapies could significantly help both patients and society. According to the CDC, arthritis affects 22.7% (52.5 million) of adults in the US (2010-2012), and the prevalence is projected to increase to an estimated 26% (78 million of the projected total adult population) by 2040.

DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Puration, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information: Media Contact email: Tel:(561)-325-8757



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store